Search - tctmd.com

Displaying 141 - 160 of 619

Sort: Relevancy | Date

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

News Conference News THT 2023

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

March 23, 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

News Conference News THT 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Yael L. Maxwell

March 22, 2023

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

News Conference News THT 2023

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

March 21, 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

March 14, 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

March 08, 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

News Conference News ACC 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

March 05, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

News Conference News CRT 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Yael L. Maxwell

March 01, 2023

Surgeons Argue: STS Data Again Show ISCHEMIA Isn’t Definitive for CABG

News Conference News STS 2023

Surgeons Argue: STS Data Again Show ISCHEMIA Isn’t Definitive for CABG

Yael L. Maxwell

January 30, 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

News Conference News STS 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

Yael L. Maxwell

January 24, 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

News Conference News ISET 2023

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

January 18, 2023

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.